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Background. Oxidative stress is well documented in multiple sclerosis (MS) lesions, but its correspondence at peripheral level is
still controversial. Objective. To evaluate peripheral oxidative stress markers in MS patients.Methods. We studied total blood levels
of Coenzyme Q
10
(CoQ
10
), oxidized and reduced forms of glutathione, malondialdehyde, reactive oxygen species (ROS), anti-
oxidized-low-density lipoproteins (anti-oxLDL) antibodies, and antioxidant power (PAO) in 87 patients with different MS clinical
phenotypes and in 77 controls. Results. CoQ
10
was lower whereas anti-oxLDL antibodies titer was higher in MS patients than in
controls. The benign variant of MS displayed both higher CoQ
10
and higher anti-oxLDL than other MS clinical variants. Female
patients had lower CoQ
10
and PAO and higher ROS than male patients. Differences were greater in younger patients with shorter
disease duration. Surprisingly, there was no difference for these markers between treated and untreated patients. Conclusion. We
found lower antioxidant agents and higher anti-oxLDL antibodies in MS, and the highest antibody titers occurred in the benign
form.We suggest that natural anti-oxLDL antibodies can be protective againstMS, saving blood brain barrier integrity. Our findings
also suggest that milder MS is associated with a distinct oxidative stress pattern, which may provide a useful biomarker of disease
prognosis.
1. Introduction
Neurodegeneration in multiple sclerosis (MS) is a multifac-
torial process manifesting from the very onset of the disease
[1, 2]. While, in the early stages of MS, neurodegeneration is
mainly driven by inflammation [3], later in the course of the
disease several interacting factors are involved. Among well-
known and less well-documented players, mitochondrial
dysfunction seems to have a crucial role [4, 5]. Mitochondrial
changes in MS include altered distribution and structure,
together with biochemical and molecular abnormalities [4,
6–9]. Mitochondrial damage is caused by several factors, in-
cluding oxidative stress [10–14]. Oxidative stress can arise in
a biological environment whenever there is an imbalance
between reactive oxygen species (ROS) production and the
cell’s buffering capacity; this imbalance results in oxidation of
proteins, lipids, andDNA [9, 15]. ROS are natural bioproducts
of oxidative phosphorylation [9, 16] but can also be generated
by activated inflammatory cells, including macrophages and
microglia [17–19]. Just as activated macrophages and mic-
roglia are an important source of ROS, oxidative stress can,
in turn, activate key factors (such as nuclear factor k Beta)
that upregulate proinflammatory gene expression [20]. Thus,
an autotoxic loop is sustained [21]. Accordingly, studies of
oxidative stress in MS have dramatically increased in recent
years [10, 22, 23]. Even though evidence of oxidative stress
damage in MS appears unequivocal, the assessment of oxida-
tive stress biomarkers has yielded inconsistent results. The
concentration of glutathione, a major antioxidant agent [10],
is increased according to some authors but decreased accord-
ing to others [24]. Similarly, uric acid, a powerful nonenzy-
matic antioxidant, was reported normal by Kastenbauer et al.
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[25], decreased by Miller and colleagues [26], and increased
by Amorini et al. [27].
These discrepancies may be due to a number of factors:
first, the use of different samples (CSF, plasma, and peripheral
blood cells) and the application of different laboratory tech-
niques; second, the choice of selected groups of oxidant or
antioxidantmarkers is likely to offer a limited and biased view
rather than a general overview of the oxidative stress phe-
nomenon. Because of the high redundancy of the antioxidant
system and the dual role played by some antioxidant scav-
engers, the decrease of one marker could be secondary and
possibly a compensatory phenomenon, rather than primary.
Finally, some inconsistencies could be due to the different
clinical phenotypes of the patients investigated.
Different clinical phenotypes of MS are characterized by
distinct histopathological features and, we hypothized, also
by distinctive oxidative stress patterns [28]. To investigate this
hypothesiswhile avoiding, asmuch as possible, the aforemen-
tioned confounding factors, we have performed a pilot trial
study comparing the levels of several oxidant and antioxidant
biomarkers in a large sample of patients with different clinical
variants of MS and in healthy control subjects.
Furthermore, we assessed the same markers in patients
exposed or nonexposed to immunosuppressive treatment.
Consistent with a previous study of oxidative stressmolecules
in other neurodegenerative diseases [29], we chose a panel
composed of the following markers: Coenzyme-Q10
(CoQ
10
); total (GSTot), oxidized (GSSG), and reduced (GSH)
forms of glutathione;malondialdehyde (MDA); reactive-oxy-
gen-species (ROS); anti-oxidized-low-density lipoproteins
antibodies (anti-oxLDL); and antioxidant power (PAO).
2. Subjects and Methods
Eighty-seven patients affected by well-established relapsing-
remitting (RR, 𝑛 = 32), benign (BB, 𝑛 = 13), primary (PP, 𝑛 =
20), or secondary progressive (SP, 𝑛 = 22) MS [30] were
recruited for the present study (MS Center Fondazione Don
Carlo Gnocchi, Milan, Italy, and CAMPolidiagnostic Center,
Monza, Italy) between July 2011 and February 2013. Patients
with relapsing-remitting course and an Expanded Disability
Status Scale (EDSS) score ≤ 3.0 after 15 years of disease were
classified as Benign MS patients [31]. All MS patients had to
be free of relapse or disease progression in the past 30 days.
We excluded patients who were treated with mitoxantrone,
cyclophosphamide, or steroids, or supplemented with nutra-
ceutical drugs or vitamins during the 3 months before blood
drawing. We also excluded patients with clinically or radi-
ologically isolated syndromes. At the time of the study, 20
patients were being treatedwith beta-interferons, 7with glati-
ramer acetate, and 7 were under other treatments (4 on natal-
izumab, 2 on azathioprine, and 1 on low dose naltrexone).
Subjects with serious or unstable medical conditions, includ-
ing cardiovascular, pulmonary, hepatic, gastrointestinal,
renal, andmetabolic diseases, malignancies, or diabetes, were
excluded from the study. After obtaining informed consent,
blood samples were collected in the morning after break-
fast and immediately delivered to the central laboratory.
Table 1: Demographic data of the studied population.
HC MS patients
𝑁 77 87
F/M 42/35 52/35 𝜒 = 0.5
Mean age (range) 46.6 (29–69) 44.1 (20–66) 𝑃 = 0.11
Median EDSS (range) — 3.0 (0–8.0)
HC: healthy controls; MS: multiple sclerosis patients.
Table 2: Demographic and clinical data of MS population.
PP SP RR BB
𝑁 20 22 32 13
F/M 7/13 13/9 22/10 10/3 𝜒 = 0.05
Mean age 45.7 45.4 40.7 47.2 𝑃 = 0.13
Mean EDSS 4.7 5.3 1.3 1.2 𝑃 < 0.001
No therapy 17 15 12 9
𝜒 < 0.001IFNB/GA 1 3 19 4
Other drugs 2 4 1 0
PP: primary progressive; SP: secondary progressive; RR: relapsing-remitting;
BB: benign; HC. Other drugs: azathioprine, natalizumab, and low dose
naltrexone.
Complete neurological examination with EDSS rating was
performed in all subjects. The demographic data of all sub-
jects are reported in Table 1. There were no significant age
differences among MS patients subgroups (Table 2) or
between HC subjects and MS patients (Table 1). The gender
distribution was analyzed using a chi-square test and there
was no significant difference between MS patients and HC
(𝑃 = 0.5). Table 2 shows a different gender and (as expected)
drug distribution across MS subgroups.
We also studied seventy-seven healthy age- and sex-
matched controls (HC).
2.1. Determination of Oxidative Stress Parameters. Whole
blood was collected in vacutainer tubes containing ethylene-
diaminetetraacetic acid (EDTA) (Becton Dickinson & Co.,
Rutherford, NJ, USA). Blood sample was centrifuged at
2500 rpm for 5 minutes to obtain serum for the detection of
CoQ
10
, MDA, and anti-oxLDL. Plasma was used to measure
PAO and ROS. An aliquot of whole blood was used for
detection of GSTot, GSSG, and GSH.
2.1.1. Coenzyme Q10. CoQ10 was determined by isocratic
HPLC and UV detection. CoQ
10
is released by protein pre-
cipitation and concentrated by solid phase extraction.
2.1.2. Malondialdehyde. Malondialdehyde (MDA) was deter-
mined by isocratic HPLC and fluorescence detection. Sample
preparation is based on a protein precipitation step, followed
by derivatisation. The resulting fluorophore is specific and
detectable at very low levels.
2.1.3. Glutathione. Glutathione (GSTot), in its reduced (GSH)
and oxidized (GSSG) form, was measured by HPLC with flu-
orescence detection. Sample preparation is based on protein
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precipitation and derivatisation. After precipitation, the sam-
ple is split into two portions. One aliquot is derivatised imme-
diately for the determination of GSH; the second aliquot
is reduced chemically before derivatisation,which leads to the
detection of both oxidized and reduced glutathione. Inclusion
of an internal standard minimizes any analytical variation.
2.1.4. Reactive Oxygen Species. We assessed reactive oxygen
species by d-ROMs test (Diacron). ROMs (primarily hydro-
peroxides and ROOH), in the presence of iron (which is
released from plasma proteins by an acidic buffer kit), gener-
ate alkoxyl (R-O∙) and peroxyl (R-OO∙) radicals through the
Fenton’s reaction. Such radicals, in turn, oxidized an alkyl-
substituted aromatic amine which acquires a 𝑡 photometri-
cally detectable pink color.
2.1.5. Antioxidant Power. Serum antioxidant levels were
measured using the Total Antioxidant Power Kit (Oxford
Biomedical Research, Oxford, MI, USA). The evaluation of
serum antioxidant levels is based on the reduction of Cu++
into Cu+. The reduced form of copper gives rise to a stable
complex with a chromogenic reagent and shows maximum
absorbance at 450 nm. Known concentrations of uric acid are
used to create a calibration curve.The values are expressed as
𝜇M copper reducing equivalents (CRE).
To assess anti-oxidized low density lipoproteins antibod-
ies, we used IMTEC-oxLDL-Antibodies Ig (GM) (IMTEC-
Human Wiesbaden, Germany). The test is based on simulta-
neous incubation of serum samples with oxLDL immobilized
into microtiter wells and native LDL immobilized on pins of
the microplate cover.
The binding of antibodies anti-oxidized LDL (anti-
oxLDL) from patient serum is detected by an anti-human
HRP conjugate and the subsequent reaction of a chromogenic
substrate.
2.2. Statistical Analysis. The normal distribution of all mea-
sured data was ascertained using the Kolmogorov-Smirnov
test. Each oxidative stress biomarker was normally dis-
tributed (all 𝑃 > 0.05). To assess group differences in oxida-
tive stress biomarkers between MS and HC, a Student’s 𝑡-test
for unpaired observations was used. Group differences bet-
ween different MS courses and HC concerning oxidative
stress biomarkers were assessed with a one-way ANOVA, fol-
lowed byTukeyHSDorDunnett 𝑡 post hoc analyses.The rela-
tionships between 2 continuous variables were examined by
Pearson’s correlation (𝑟). All statistical analyses were per-
formedwith the SPSS statistical software package version 15.0
(SPSS, Chicago, IL, USA). Statistical significance was taken to
be at the two-tailed 0.05 level.
3. Results
The levels of oxidative stress biomarkers in the studied popu-
lation are shown in Table 3.
CoQ
10
, a potent antioxidant involved in energy meta-
bolism, was lower in MS patients than in HC subjects (𝑃 =
0.001) (Figure 1(a)).
BB patients had higher value of CoQ
10
than all other
groups. Post hoc analysis showed a significant difference bet-
ween BB and RR (𝑃 < 0.05) (Figure 1(b)). Anti-oxLDL,
natural antibodies reacting with bioproducts of lipid perox-
idation, were higher in MS patients than in HC (𝑃 = 0.038)
(Figure 1(d)). Post hoc analysis revealed a significant differ-
ence between HC and BB patients (𝑃 = 0.013) (Figure 1(e)).
No statistically significant differences between patients and
controls were found for GSTot, GSSG, GSH, MDA, and ROS,
and there was only a trend toward decrease of serum-anti-
oxidant power (PAO) inMS patients as compared toHC (𝑃 =
0.055).
InMS patients, we found significant correlations between
levels of PAO andCoQ
10
(𝑟 = 0.36,𝑃 = 0.01), PAO andGStot
(𝑟 = 0.43, 𝑃 < 0.01), and PAO and GSH (𝑟 = 0.44, 𝑃 < 0.01).
This finding confirms that CoQ
10
and Glutathione are crucial
in determining antioxidant response. Moreover, there was a
negative correlation between MDA and Anti-oxLDL levels
(𝑟 = −0.29, 𝑃 = 0.04), suggesting these autoantibodies as
contributory factor in scavenging oxidized-lipids.
It has been reported that oxidative stress naturally
increases with aging, and it is known that antioxidant factors
aremodulated by gender [32–34]. Accordingly, we performed
additional analyses after stratification for age and gender.
CoQ
10
was lower in MS patients younger than 49 years than
in age-matched HC (𝑃 = 0.005) (Table 4 and Figure 1(c)).
Conversely, anti-oxLDL level was higher in MS patients
younger than 49 years than in age-matched HC (𝑃 = 0.024)
(Table 4 and Figure 1(f)). No significant differences were
found for PAO levels and other oxidative biomarkers (data
not shown).
Interestingly, we found lower antioxidant molecules
(CoQ
10
, 𝑃 = 0.007; PAO, 𝑃 < 0.001) and higher bioproducts
of oxidative stress (ROS,𝑃 < 0.001) in healthy females than in
male counterparts (Figure 2(a)). Similar gender-related dif-
ferences were found in MS patients for CoQ
10
, PAO (MS
females lower than MS males, 𝑃 = 0.034 and 𝑃 < 0.001,
resp.), and ROS (MS females higher than MS males 𝑃 =
0.005) (Figure 2(b)). ComparingHC and patients, CoQ
10
was
lower in MS females than in HC females (𝑃 = 0.013)
(Figure 2(c)).
Guided by the hypothesis that higher oxidative stress
damage contributes to higher disease severity [9], we investi-
gated a possible correlation betweenMS severity and antioxi-
dant levels. We used EDDS scale as rough index of MS sever-
ity and we measured a correlation with any of the markers
investigated. No statistical difference was found both using
parametric (Pearson) and nonparametric tests (Spearman)
(see supplementary Tables 7 and 8 in supplementary material
available online at http://dx.doi.org/10.1155/2014/961863).
In addition, we measured disease progression rate
(defined as the ratio between EDSS score and years of disease
duration) and grouped patients according to the median of
this value (0.36).
We investigated a possible correlation between progres-
sion rate and CoQ
10
or anti-oxLDL (previously reported as
different between studied groups). CoQ
10
levels showed a
trend toward increase in patients with progression rate <0.36
(CoQ
10
= 530.67 ± 281.54) than in patients with progression
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Table 3: Oxidative stress markers’ distributions in MS patients and HC.
CoQ10
𝜇g/L
MDA
𝜇g/L
GSTot
mg/L
GSH
mg/L
GSSG
mg/L
PAO
𝜇mol
Anti-oxLDL
U/mL
ROS
UCarr
MS 483.79 ± 253.75 7.58 ± 3.22 371.05±120.97 317.26 ± 124.76 56.74 ± 27.63 965.03 ± 166.75 33.95 ± 19.48 315.15 ± 93.58
PP 493.25 ± 242.35 7.72 ± 3.85 363.73 ± 84.09 314.96 ± 95.63 48.22 ± 21.71 996.26 ± 142.00 31.16 ± 14.66 301.44 ± 68.30
SP 464.76 ± 182.25 7.71 ± 3.14 341.43±151.54 286.84 ± 150.6 56.48 ± 27.43 931.95 ± 182.43 33.57 ± 16.46 303.191 ± 81.8
RR 429.20 ± 199.29 7.81 ± 3.05 396.28±116.91 336.06 ± 109.51 62.97 ± 30.02 955.09 ± 162.09 31.89 ± 19.8 320.43±121.25
BB 635.78 ± 417.05 6.60 ± 2.92 370.3 ± 121.60 326.04 ± 153.84 55.87 ± 29.75 999.85 ± 188.31 43.98 ± 27.55 341.23 ± 66.95
HC 616.13 ± 234.19 7.10 ± 2.46 360.43 ± 99.65 309.21 ± 102.28 51.21 ± 33.29 1018.25 ± 180.38 28.08 ± 15.67 315.31 ± 77.4
𝑃
†
<0.001 0.30 0.55 0.66 0.26 0.06 0.04 0.99
𝑃
‡
<0.001 0.59 0.46 0.62 0.39 0.22 0.013 0.71
Data are expressed as mean ± SD. MS: multiple sclerosis; PP: primary progressive; SP: secondary progressive; RR: relapsing-remitting; BB: benign; HC: healthy
controls.𝑃†: comparing all MS patients withHC (Student’s 𝑡-test was used);𝑃‡: each disease course was compared withHC: only BBwere significantly different
from HC, 𝑃 = 0.013 (ANOVA was used).
CoQ10: a potent antioxidant involved in energy metabolism was lower in MS patients than in HC subjects (𝑃 = 0.001) (Figure 1(a)).
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Figure 1: Bar plot showing mean values, and bars represent SD. (a) CoQ
10
levels in healthy controls (HC) and multiple sclerosis patients
(MS), 𝑃 = 0.001; (b) CoQ
10
levels in HC, primary progressive (PP), secondary progressive (SP), relapsing-remitting (RR), and benign (BB)
MS, 𝑃 < 0.05; (c) CoQ
10
in HC andMS stratified for age (49 years: median age), ∗𝑃 = 0.005; (d) anti-oxLDL levels in HC andMS, 𝑃 = 0.038;
(e) anti-oxLDL levels in HC, PP, SP, RR, and BB, 𝑃 = 0.013; (f) anti-oxLDL levels in HC and MS stratified for age, 𝑃 = 0.024.
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Table 4: Oxidative stress markers’ distributions in MS patients according to treatment.
MS No therapy(𝑛 = 53)
IFNB/GA
(𝑛 = 27)
Other therapies
(𝑛 = 7)
HC
(𝑛 = 77) 𝑃
a
𝑃
b
𝑃
t
Q10 536.04 ± 286.19 398.9 ± 189.48 452.35 ± 91.1 616.13 ± 234.19 0.072 0.103 0.001
MDA 7.47 ± 3.57 7.87 ± 2.92 7.58 ± 1.85 07.10 ± 02.46 0.879 0.460 0.30
Glu tot 351.37 ± 109.63 386.38 ± 127.65 453.81 ± 149.17 360.43 ± 99.65 0.063 0.113 0.55
GSH 299.93 ± 119.14 322.22 ± 120.88 413.09 ± 151.01 309.21 ± 102.28 0.056 0.102 0.66
GSSG 54.98 ± 26.59 64.16 ± 28.74 47.28 ± 24.81 51.21 ± 33.29 0.247 0.213 0.26
PAO 961.8 ± 174.98 982.73 ± 149.55 960.0 ± 168.77 1018.25 ± 180.38 0.865 0.929 0.06
Anti-oxLDL 32.93 ± 19.08 37.22 ± 19.77 32.00 ± 22.92 28.08 ± 15.67 0.631 0.517 0.04
ROS 313.85 ± 102.91 317.12 ± 76.64 320.87 ± 94.09 315.31 ± 77.4 0.977 0.940 0.99
No therapy: patients not under DMDs. IFNB/GA: patients using IFNBeta or glatiramer acetate. Other therapies: patients under other treatments (4 on
natalizumab, 2 on azathioprine, and 1 on low dose naltrexone) HC: healthy controls. Data are expressed as mean ± SD. Using both parametric (𝑃a = ANOVA)
and nonparametric (𝑃b) tests, no statistical significant differences were found according to treatment. 𝑃t shows statistically significant differences between all
MS patients and HC.
rate≥0.36 (CoQ
10
= 452.51±218.54) but it was not significant
(𝑃 = 0.164). Concerning anti-oxLDL, no statistically signifi-
cant difference (𝑃 = 0.539) betweenpatientswith progression
rate <0.36 (Anti-oxLDL 36.15 ± 22.43) and patients with
progression rate ≥0.36 (Anti-oxLDL 33.45±16.76) was found
(data reported in Figure 3).
CoQ
10
levels showed just a trend toward increase in
patients with progression rate <0.36 (CoQ
10
= 530.67 ±
281.54) than in patients with progression rate≥0.36 (CoQ
10
=
452.51 ± 218.54, 𝑃 : n.s.). However, we found no statistically
significant difference in anti-oxLDL between patients with
progression rate <0.36 (anti-oxLDL 36.15 ± 22.43) and
patients with progression rate ≥0.36 (anti-oxLDL 33.45 ±
16.76).
Because some interferons can modulate cellular antiox-
idant responses [35], we assessed a possible influence of
disease-modifying drugs (i.e., IFNb andGlatimerAcetate) on
oxidative stress parameters, but we found no differences in
oxidative stress biomarker levels between patients treated
with immunomodulant (𝑛 = 27) or immunosuppressive
drugs (natalizumab and azathioprine, 𝑛 = 7) or under no
treatment (Table 4).
4. Discussion
Inflammation and neurodegeneration are intertwined pro-
cesses present since the early stages of MS [3]. Among the
several factors that have been involved in these mechanisms,
oxidative stress damage has been the focus of numerous stud-
ies [10, 22, 23, 28, 36–39]. However, the timing, the degree,
and the mechanisms by which oxidative stress contributes
to MS tissue damage are still unclear. Histopathological data
of Haider and colleagues [39] show that oxidative damage is
massively present inside active lesions in areas of initial
demyelination, at a stage regarded as a prephagocytic [40].
The same group described a deregulation of mitochondrial
genes involved in redox homeostasis, whichwasmore evident
in initial lesions than in established demyelinated lesions,
suggesting that oxidative stress damage associated with early
mitochondria dysfunction occurs during the first stages of
the disease [9]. At the beginning of MS, cellular antioxidant
defenses may control oxidative stress. However, this home-
ostasis is lost as oxidation processes increase, typically during
systemic inflammation or if the antioxidant buffer system is
depleted (i.e., due to energetic failure) and tissue damage
ensues. The severity of the imbalance between oxidative
agents and antioxidant defenses may thus contribute to
determine disease severity.
In fact, our results show that a higher antioxidant factor
(CoQ
10
) is associatedwith a less disabling course ofMS (i.e., a
benign phenotype).This finding cannot be simply ascribed to
a different demographic profile of benign MS (Table 2). The
treatment regimen, which is clearly milder in benign MS
patients, does not have any influence onCoQ
10
or anti-oxLDL
levels, because there was no difference between treated and
untreated MS patients (Table 4). This finding is bolstered by
the fact that the higher female/male ratio in benignMS (com-
pared to other subgroups) should have, if anything, lowered
CoQ
10
because females have lower CoQ
10
levels both in
health controls and in MS.
CoQ
10
is a constituent of the proton\electron trans-
port chain, crucially involved in energy production [41].
Moreover, it acts as a primary scavenger of free radicals,
protecting membrane phospholipids, proteins, and mtDNA
from oxidative damage and favoring the regeneration of
other antioxidants, such as tocopherol and ascorbate. It was
also documented that CoQ
10
is a calcium stabilizer, capable
of alleviating calcium overload [42], and it has anti-inflam-
matory properties because it inhibits metalloproteinases and
IL-6 production [43]. Recently, CoQ
10
supplementation in
45 RR MS resulted in an increase of superoxide dismutase
activity and a decrease inMDA levels comparedwith controls
over 12 weeks of a randomized, double-blinded, placebo-
controlled trial [44].
The higher levels of CoQ
10
detected by our study in
benignMS are consistent with a greater antioxidant buffering
ability in these patients. Interestingly, CoQ
10
difference bet-
ween HC and MS patients has been seen in subjects younger
than 49 years whereas it disappears in older patients. Of note,
the first group shows also a shorter disease duration
6 Journal of Immunology Research
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Figure 2: CoQ
10
, PAO, ROS levels related to gender. Bar plot showing mean values, bars represent SD. (a) CoQ
10
levels in in Female and
Male HC, 𝑃 = 0.034; (b) CoQ
10
levels in Female andMale MS, 𝑃 = 0.007; (c) CoQ
10
levels in Female HC and Female MS, 𝑃 = 0.013; (d) PAO
levels in Female and Male HC, 𝑃 = 0.000; (e) PAO levels in Female and Male MS, 𝑃 = n.s.; (f) CoQ
10
levels in Female HC and Female MS,
𝑃 = 0.000; (g) ROS levels in Female and Male HC, 𝑃 = 0.000; (h) ROS levels in Female and Male MS, 𝑃 = 0.005; (i) ROS levels in Female HC
and Female MS, 𝑃 = n.s.
(𝑃 = 0.005) compared to the latter. This data supports the
hypothesis that oxidative stress is crucial since the early stages
of MS as the previously collected histopathological findings
have shown [9, 11]. The different ability of patients to cope
with oxidative stress may be fundamental in determining
their long-term disease course.
The finding that CoQ
10
levels are lower in females than in
males, irrespective of disease status, may suggest that lower
antioxidant protection can be a contributing factor in the
well-known female prevalence of MS [45].
The low levels of CoQ
10
we measured are only apparently
inconsistent with the results of de Bustos et al. [46], who
found no difference between MS and HC subjects. The MS
population studied by these authors corresponds exactly to
the one that we excluded from our study (patients duringMS
exacerbation). The normal CoQ
10
levels they found in
patients compared toHC could be explained by an attempt by
the organism to increase antioxidant mechanisms during
an inflammatory phase of disease. This phase-dependent
increase might thus compensate constitutive low level of
CoQ
10
.
Benign MS is associated with higher titers of anti-oxLDL
antibodies. Antibodies directed against oxLDL reactwith bio-
products of lipid peroxidation, such as oxidized lipoproteins.
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Figure 3: Bar plot show mean values, and bars represent SD. (a) CoQ
10
levels in MS patients with progression rate <0.36 and progression
rate >0.36 (𝑃 = 0.164); (b) anti-oxLDL levels in MS patients with progression rate <0.36 and progression rate >0.36 (𝑃 = 0.539).
These antibodies are thought to have a protective effect in
atherosclerosis, where oxidation of lipoproteins is a critical
event in the progression of atherogenesis [47–49].
OxLDL colocalizes with proinflammatory cells in athero-
sclerotic lesions and possesses a wide spectrum of highly
immunogenic oxidation-specific epitopes (both lipid and
protein components of LDL) [50]. Recent studies show that
oxidized phospholipids favor monocyte binding to endothe-
lial cells, thus promoting diapedesis from the blood stream
[51]. Anti-oxLDL reacting with oxidized phospholipids could
counteract this pathogenetic mechanism.
In addition, OxLDL is known to affect the integrity of the
blood-brain barrier [52–54] andmay contribute to the forma-
tion of perivascular infiltrates. Thus, increased levels of anti-
OxLDL may also impair cells extravasation and inhibit the
mechanisms leading to the infiltration of inflammatory cells
into the brain.
Considering the high polyreactivity of anti-oxLDL anti-
bodies [55], it is reasonable to think that they may also bind
lipid epitopes on myelin debris. Benign patients may there-
fore have an increased ability to remove myelin remnants.
Myelin debris scavenging activity could reduce an important
chemoattractant signal for inflammatory cells and facilitate
remyelination processes at the same time. Unfortunately, the
lack of detailed data concerning these antibodies (i.e., class,
immune-phenotyping of secreting B cells) makes these
hypotheses only speculative at themoment.Here, we can only
report the association between better prognosis and higher
levels of anti-oxLDL antibodies. We cannot clarify whether
these autoantibodies are an epiphenomenon of demyelina-
tion (but in this case, they should be increased inmore severe
cases) or are part of a healing attempt facilitating remyelina-
tion.
The higher anti-oxLDL antibodies levels that we found in
benign MS are in line with the higher CoQ
10
levels that we
documented in this subgroup, suggesting that, in general, a
greater antioxidant ability is associated with a milder MS
course. Curiously, neither MS severity (measured by EDDS)
nor disease progression (measured by progression rate)
impacts these oxidative markers.This finding could favor the
hypothesis that a depletion in antioxidant is not merely a
consequence of mobility constraint (we should have found
lower CoQ
10
and another antioxidant associated with higher
EDSS). In fact, this finding sounds to suggest antioxidant
depletion as an intrinsic, and probably causative, factor asso-
ciated with severe MS courses rather than its consequence.
No statistical correlation was found between anti-OxLDL
and CoQ
10
levels. This finding confirms that these variables
are independent, suggesting that themechanisms counteract-
ing oxidative damage are diverse. Conversely, lower values of
anti-OxLDL were fairly well associated with higher MDA, a
marker of lipid peroxidation, suggesting the involvement of
these autoantibodies in the clearance of oxidized lipids.
Another interesting finding to be highlighted is a trend
toward a relative PAO deficiency in MS patients as compared
to healthy controls (𝑃 = 0.055). Decreased plasma antioxi-
dant capacity has been reported by several authors [10, 26, 39,
56], confirming the hypothesis that the antioxidant system is
defective in MS.
MS is a CNS disorder and it is still a matter of debate how
the immunological, biochemical, and oxidative abnormalities
occurring in the periphery reflect the “central” phenomenon.
To address this issue, we tried to investigate the same panel of
oxidative biomarkers in a subgroup of patients undergoing a
diagnostic spinal tap. Unfortunately, given the small amount
of CSF that we considered ethical to utilize for this research,
we could not obtain consistent results (data available for
further analyses). Arguably, CoQ
10
levels were below the
detectability threshold even with the sophisticated method
employed.
Notwithstanding these technical restrictions, we believe
that our findings should trigger prospective studies aimed at
addressing the potential role of an oxidative panel as a bio-
marker of disease course.
5. Conclusions
Oxidative stress markers can be different across MS courses.
Indeed, benign MS patients show higher antioxidant factors,
includingCoQ
10
and anti-OxLDL autoantibodies, whichmay
8 Journal of Immunology Research
confer protection against oxidative stress-drivenmechanisms
of neurodegeneration.
Several studies suggest that antioxidant enzymes activity
is associated with the presence of neuroinflammation and
oxidative damage [57]. Enhanced antioxidant mechanisms
may represent a natural compensatorymechanismprotecting
against direct oxidative damage and avoiding an indirect
inflammatory enhancing system. Higher CoQ
10
and anti-
oxLDL antibodies found in benign courseMS can disclose an
alternative mechanism explaining the better prognosis of this
phenotype.These preliminary data should prompt additional
and possibly longitudinal studies to investigate the potential
role of these molecules as biomarkers and predictors of
disease course.
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